Ciphergen Announces Publication of Data Describing Application for Evaluating Patients with Blood Disorder
January 29 2007 - 9:00AM
PR Newswire (US)
FREMONT, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) today announced that its clinical
development partner Ohio State University published an article
describing the use of Surface Enhanced Laser Desorption/Ionization
Time of Flight (SELDI-TOF) mass spectrometry for the diagnosis and
clinical evaluation of thrombotic thrombocytopenic purpura (TTP), a
hematologic disease. The article appears in the current issue of
Spectroscopy. "A diagnostic test that can rapidly determine enzyme
activity is needed to help clinicians make the correct diagnosis,
initiate timely therapy and predict the risk of the disease
recurrences for patients with thrombotic thrombocytopenic purpura,
a devastating hematological disorder," said Haifeng M. Wu, M.D.,
Assistant Professor of Pathology and Medicine and Director of
Clinical Coagulation Laboratory at Ohio State University Medical
Center, author of the paper and Ciphergen collaborator. "This study
successfully illustrates the unique application of SELDI-TOF mass
spectrometry for measuring enzyme activity and evaluating
auto-antibody activity -- both of which are key parameters in the
pathology and progression of TTP." In November 2006, Ciphergen and
OSU announced a collaborative agreement to develop and clinically
validate a diagnostic test to detect TTP. Under the terms of the
agreement, and Ciphergen will optimize the assay to measure enzyme
and antibody inhibition activity, and will jointly conduct
multi-center studies to validate the test. Ciphergen Biosystems and
Ohio State University intend to validate the assay's clinical
utility using SELDI-TOF technology across a larger patient
population. About Thrombotic Thrombocytopenic Purpura (TTP) TTP is
a blood disorder characterized by low platelets, low red blood cell
count (caused by premature breakdown of the cells), neurological
abnormalities and sometimes abnormalities in kidney function. In
most cases, this disease is caused by a deficiency in or
auto-antibodies to an enzyme called ADAMTS13, which cleaves von
Willebrand Factor. Loss of this enzyme causes platelet clumping and
red blood cell destruction that are the hallmarks of TTP. About
Ciphergen Ciphergen Biosystems, Inc. is dedicated to the discovery,
development and commercialization of novel high-value diagnostic
tests that help physicians diagnose, treat and improve outcomes for
patients. Ciphergen, along with its prestigious scientific
collaborators, has ongoing diagnostic programs in
oncology/hematology, cardiology and women's health with an initial
focus in ovarian cancer. Based in Fremont, California, more
information about Ciphergen can be found on the Web at
http://www.ciphergen.com/. Safe Harbor Statement Note Regarding
Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such forward-looking
statements include statements regarding the utility of using
SELDI-TOF mass spectrometry for measuring enzyme activity and
evaluating auto-antibody activity and Ciphergen's efforts to
optimize an assay for such measurements to be used in a diagnostics
test. Actual results may differ materially from those projected in
such forward-looking statements due to various factors, including
the possibility that Ciphergen's efforts may not proceed as
anticipated. Investors should consult Ciphergen's filings with the
Securities and Exchange Commission, including its Form 10-Q filed
November 20, 2006, for further information regarding these and
other risks related to the Company's business. NOTE: Ciphergen is a
registered trademark of Ciphergen Biosystems, Inc. DATASOURCE:
Ciphergen Biosystems, Inc. CONTACT: Investors, Sue Carruthers of
Ciphergen Biosystems, Inc., +1-510-505-2233, or Media, Lori Murray
of WeissComm Partners, +1-415-946-1070 Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Apr 2024 to May 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2023 to May 2024